Galsky M - Search Results

1

Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.

Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK. Smaletz O, et al. Among authors: galsky m. Ann Oncol. 2003 Oct;14(10):1518-24. doi: 10.1093/annonc/mdg415. Ann Oncol. 2003. PMID: 14504052 Free article. Clinical Trial.

2

The development of differentiation agents for the treatment of prostate cancer.

Galsky M, Kelly WK. Galsky M, et al. Semin Oncol. 2003 Oct;30(5):689-97. doi: 10.1016/s0093-7754(03)00355-5. Semin Oncol. 2003. PMID: 14571416 Review.

3

Use of nomograms for predicting survival in patients with castrate prostate cancer.

Galsky M, Kelly WK. Galsky M, et al. Urology. 2003 Dec 29;62 Suppl 1:119-27. doi: 10.1016/j.urology.2003.09.003. Urology. 2003. PMID: 14747049 Review.

4

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Galsky MD, et al. J Clin Oncol. 2005 Mar 1;23(7):1439-46. doi: 10.1200/JCO.2005.09.042. J Clin Oncol. 2005. PMID: 15735119 Clinical Trial.

5

Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?

Galsky MD, Scher HI. Galsky MD, et al. J Clin Oncol. 2005 Aug 1;23(22):4823-6. doi: 10.1200/JCO.2005.92.001. Epub 2005 Jun 6. J Clin Oncol. 2005. PMID: 15939919 No abstract available.

6

Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.

Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Ross RW, et al. Among authors: galsky m. Clin Cancer Res. 2005 Jul 15;11(14):5195-8. doi: 10.1158/1078-0432.CCR-05-0431. Clin Cancer Res. 2005. PMID: 16033836

7

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. Rosenberg JE, et al. Cancer. 2006 Jan 1;106(1):58-62. doi: 10.1002/cncr.21559. Cancer. 2006. PMID: 16329138 Free article.

8

Violaceous exanthem as a manifestation of metastatic prostate cancer in skin.

Slovin SF, Galsky MD, Busam K. Slovin SF, et al. Urology. 2006 Feb;67(2):420. doi: 10.1016/j.urology.2005.08.033. Urology. 2006. PMID: 16461102 No abstract available.

9

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Galsky MD, et al. Invest New Drugs. 2007 Jun;25(3):265-70. doi: 10.1007/s10637-006-9020-9. Epub 2006 Dec 5. Invest New Drugs. 2007. PMID: 17146733 Clinical Trial.

10

High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?

Galsky MD, Kelly WK. Galsky MD, et al. Nat Clin Pract Urol. 2007 Mar;4(3):134-5. doi: 10.1038/ncpuro0731. Epub 2007 Feb 13. Nat Clin Pract Urol. 2007. PMID: 17297500 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

429 results

Search Page

Filters